Clinical Trials
15 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04553133 2026-05-06
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
Phase 2 Active not recruiting
NCT02664935 2026-04-28
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Completed
NCT04606446 2026-04-16
KAT6
Pfizer
Phase 2 Recruiting
NCT03170206 2026-02-12
Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02022982 2024-03-19
PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT06307249 2024-03-12
PTST_PALBEVA
Lebanese University
Phase 1 Recruiting
NCT04870034 2023-12-22
Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT03386929 2023-12-18
SPRING
Worldwide Innovative Network Association
Phase 1/2 Terminated
NCT02897375 2023-10-10
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Emory University
Phase 1 Completed
NCT06065592 2023-10-06
CAT_PB
Lebanese University
Phase 1 Unknown
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT03965845 2022-09-19
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Calithera Biosciences, Inc
Phase 1/2 Completed
NCT02349633 2021-06-10
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
Pfizer
Phase 1/2 Terminated
NCT01291017 2016-05-13
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.
University of Florida
Phase 2 Completed